Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Discussion
The U.S. Food and Drug Administration has designated Darzalex (daratumumab), in combination with standard-of-care regimens, a breakthrough therapy for people with previously treated multiple myeloma (MM), speeding…
Discussion
A randomized Phase 3 clincal trial has concluded that combining bortezomib (Velcade) with pegylated liposomal doxorubicin (PLD) does not show benefit in treating relapsed or refractory…
Discussion
Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition…
Discussion
A study has uncovered that elevated body mass index (BMI), a measurement of obesity, increases an individual’s risk of developing multiple myeloma and the disease’s…
Discussion
Researchers at the University of Birmingham have found that blocking a specific mechanism in the benign condition monoclonal gammophaty of undetermined significance (MGUS) may prevent the development…
Discussion
In the largest study to date, researchers from The Institute of Cancer Research in London identified eight new gene mutations increasing the risk of developing…
